Timolol- Dorzolamide- Latanoprost P-F — Class II drug recall D-1579-2019
Terminated recall by ImprimisRx NJ, reported 2019-08-07, distributed nationwide. Subpotent Drug
| Recall number | D-1579-2019 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | ImprimisRx NJ, Ledgewood, NJ, United States |
| Recall initiated | 2019-07-17 |
| Classified | 2019-07-31 |
| Reported by FDA | 2019-08-07 |
| Terminated | 2020-04-22 |
| Distributed | Nationwide (US) |
| Quantity | 246 bottles |
| Reason classes | potency |
| Expiration dates | 2019-09-17, 2019-11-02 |
Product
Timolol- Dorzolamide- Latanoprost P-F (0.5/2.0/0.005%) ophthalmic drops, packaged in 5mL bottles, Rx only, ImprimisRx NJ 1705 Route 46 West, Suite 4, Ledgewood, NJ 07852 (844) 446-6979
Reason for recall
Subpotent Drug
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1579-2019. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.